Intervention not reported
All cause mortality ‐ End of · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in all cause mortality ‐ End of (low certainty).
1 finding from 1 review
Intervention not reported
All cause mortality subgroup analysis age>60 · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in all cause mortality subgroup analysis age>60 (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality subgroup analysis age< 60 · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in all‐cause mortality subgroup analysis age< 60 (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality ‐ sensitivity analysis · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in all‐cause mortality ‐ sensitivity analysis (high certainty).
1 finding from 1 review
Intervention not reported
Overall survival · Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia
The intervention showed no clear difference in overall survival (low certainty).
1 finding from 1 review
Intervention not reported
complete response · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in complete response (moderate certainty).
1 finding from 1 review
Intervention not reported
Disease free survival · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in disease free survival (low certainty).
1 finding from 1 review
Intervention not reported
Relapse rate · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in relapse rate (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival Median · patients with indolent B cell lymphoid malignancy
1 finding from 1 review
Intervention not reported
All‐cause mortality Median · patients with indolent B cell lymphoid malignancy
1 finding from 1 review
Mortality Median · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate showed no clear difference in mortality (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Progression/relapse · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate probably leads to lower progression/relapse (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Treatment‐related mortality · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate showed no clear difference in treatment‐related mortality compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with primary CNS lymphoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse effects (grade 3+): Infection · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate probably leads to higher infections (grade 3 to 4) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (0 to 26 months) · Haemopoietic stem cell donors
The intervention showed no clear difference in mortality (0 to 26 months) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events (day 7 to day 30 post‐donation) · Haemopoietic stem cell donors
1 finding from 1 review
Intervention not reported
Pain subsequent to donation ("after collection" ‐ day 30 post‐donation) · Haemopoietic stem cell donors
1 finding from 1 review
Intervention not reported
Psychological morbidity (immediately ‐ day 28 post‐donation) · Haemopoietic stem cell donors
1 finding from 1 review